Lysophosphatidic acid (LPA) is a simple phospholipid consisting of a phosphate group,
glycerol moiety, and only one hydrocarbon chain. Despite its simple chemical structure, LPA …

Stroke is a major reason for disability and the second highest cause of death in the world.
When a patient is admitted to a hospital, it is necessary to identify the type of stroke, and the …

Lysophosphatidic acid (LPA) is an extracellular lipid mediator involved in many
physiological functions that signals through six known G-protein-coupled receptors (LPA1 …

Background Lysophosphatidic acid receptor 1 (LPA 1) is in the spotlight because its
synthetic antagonist has been under clinical trials for lung fibrosis and psoriasis. Targeting …

Abstract Central Post-Stroke Pain (CPSP) is a primary sequelae of stroke that can develop in
the body part corresponding to the cerebrovascular lesion after stroke, most typically after …

Background: Paclitaxel, which is widely used for the treatment of solid tumors, causes
neuropathic pain via poorly understood mechanisms. Previously, we have demonstrated …

We developed a mouse model for central post-stroke pain (CPSP), a centrally-originated
neuropathic pain (NeuP). In this mode, mice were first injected with Rose Bengal, followed …

Chemical mediators stimulate their receptors on nociceptor endings of sensory neurons,
activate various types of ion channels through intracellular signaling, and generate action …

Lysophosphatidic acid (LPA) has major roles as a bioactive signaling molecule, with
multiple physiological and pathological roles being described in almost every major organ …

Since the first discovery that the bioactive lipid, lysophosphatidic acid (LPA) and LPA1
receptor signaling play a role in the initiation of neuropathic pain (NeuP), accumulated …